FindTrial
Sign In

Neofordex 40 mg tablets

DRUG5 trials

Sponsors

Pfizer Inc., Kite Pharma Inc., Intergroupe Francophone Du Myelome, Assistance Publique Hopitaux De Paris

Conditions

AL AmyloidosisAdult patients with immune thrombocytopenia (ITP) with mild to severe bleeding manifestationsMULTIPLE MYELOMAMultiple MyelomaRelapsed/refractory multiple myeloma in patients who have received 1 to 3 prior lines of therapy and have been exposed to both an immunomodulatory drug and an anti-CD38 monoclonal antibody

Phase 2

A phase 2, open label, multicenter, single-stage study to evaluate the efficacy of Isatuximab plus Pomalidomide and Dexamethasone (IPd), in patients with AL amyloidosis not in VGPR or better after any previous therapy
Not yet recruitingCTIS2024-513887-25-00
Intergroupe Francophone Du MyelomeAL Amyloidosis
Target: 30Updated: 2025-12-19

Phase 3

C1071005 - MAGNETISMM-5: AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR
Active, not recruitingCTIS2023-509208-14-00
Pfizer Inc.MULTIPLE MYELOMA
Start: 2021-09-28Target: 414Updated: 2025-10-01
Intravenous Immunoglobulin plus oral prednisone or high-dose dexamethasone, for adults with immune thrombocytopenia (ITP) with moderate and severe bleeding: a randomized, multicentre trial (IVIORDEX)
RecruitingCTIS2024-516403-16-00
Assistance Publique Hopitaux De ParisAdult patients with immune thrombocytopenia (ITP) with mild to severe bleeding manifestations
Start: 2022-04-07Target: 272Updated: 2025-05-27
MInimal residual Disease Adapted Strategy / IFM 2020-02: frontline therapy for patients eligible for autologous stem cell transplantation less than 66 years; a prospective study from the French cooperative group IFM
Not yet recruitingCTIS2024-513889-19-00
Intergroupe Francophone Du MyelomeMultiple Myeloma
Target: 791Updated: 2025-09-24
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
RecruitingCTIS2024-511188-26-00
Kite Pharma Inc.Relapsed/refractory multiple myeloma in patients who have received 1 to 3 prior lines of therapy and have been exposed to both an immunomodulatory drug and an anti-CD38 monoclonal antibody
Start: 2024-12-20Target: 192Updated: 2025-09-12